PPP3CA and chronic kidney disease: Several networks recapitulated pathways already targeted by late-stage or approved CKD therapies, serving as internal positive controls (such as the inhibition of C3-related disease by pegcetacoplan, or the inhibition of the PPP3CA-NFAT axis by calcineurin inhibitors Fig 6A)25–27.